LINCOLNSHIRE, Ill. - May 18, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will be presenting at two upcoming investors conferences on May 24, 2011.
http://cc.talkpoint.com/ubsx001/052411a_im/?entity=12_P5QEHBK. The webcast will be archived after the live event and will be available for 180 days.
Phillip B. Donenberg, BioSante's senior vice president of finance and CFO, will speak on May 24, 2011 at 11:30 am PT at the 7th Annual Spring Growth Stock Conference hosted by Security Research Associates, Inc. The conference will be held on Tuesday, May 24th at the Omni Hotel in San Francisco.
Both speakers will provide an overview of the BioSante, as well as an update on the LibiGel� (testosterone gel) Phase III clinical development program.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
The Trout Group LLC
(312) 944-6784 ext. 316
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).